Jeon Kyeongman, Kim Hojoong, Yu Chang-Min, Koh Won-Jung, Suh Gee Young, Chung Man Pyo, Kwon O Jung
Division of Pulmonary and Critical Care Medicine, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
J Thorac Oncol. 2006 May;1(4):319-23.
Bronchoscopic intervention in patients with malignant central airway obstruction provides initial palliation and stabilization of the airway, allowing the possibility of other effective therapeutic modalities, such as surgery, radiation, or chemotherapy. In critically ill patients, however, the only studies of bronchoscopic intervention are relatively small series.
To describe the advantages and limitations of rigid bronchoscopic intervention in critically ill patients, we reviewed the medical records of 36 patients (26 men; median age, 62 years; range, 29 to 76 years) who underwent emergency airway intervention for malignant central airway obstruction.
Dyspnea was relieved in 34 of 36 patients (94.4%). After the airway was widened, additional definitive therapeutic modalities were used for 21 of 34 patients (61.8%). Patients who underwent additional definitive therapy after bronchoscopic intervention survived longer (median, 38.2 months; range 1.7 to 57.0 months) than those who did not (median, 6.2 months; range, 0.1 to 33.7 months; p < 0.001).
These data show that rigid bronchoscopic intervention in critically ill patients with malignant central airway obstruction may be temporarily life-saving and, in some patients, may serve as a "bridge" to allow time for additional therapies for longer survival.
对恶性中央气道阻塞患者进行支气管镜介入可实现气道的初步姑息治疗和稳定,从而使其他有效治疗方式(如手术、放疗或化疗)成为可能。然而,对于重症患者,有关支气管镜介入的研究仅为相对较小的系列研究。
为描述硬质支气管镜介入在重症患者中的优势和局限性,我们回顾了36例因恶性中央气道阻塞接受紧急气道介入治疗的患者(26例男性;中位年龄62岁;范围29至76岁)的病历。
36例患者中有34例(94.4%)的呼吸困难得到缓解。气道扩张后,34例患者中有21例(61.8%)采用了其他确定性治疗方式。支气管镜介入后接受其他确定性治疗的患者生存期长于未接受者(中位生存期38.2个月;范围1.7至57.0个月)(中位生存期6.2个月;范围0.1至33.7个月;p<0.001)。
这些数据表明,对患有恶性中央气道阻塞的重症患者进行硬质支气管镜介入可能具有暂时挽救生命的作用,并且在某些患者中可作为“桥梁”,为进行其他治疗以延长生存期争取时间。